XTL BIOPHARMACEUTICALS LTD. Deferred Tax Expense Income
XTL BIOPHARMACEUTICALS LTD. (XTLB) reported Deferred Tax Expense Income of -$130.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2025-04-30
| Period end | Deferred Tax Expense Income 12 month |
|---|---|
| 2024-12-31 | -$130.00K 20-F · filed 2025-04-30 |